US Stock MarketDetailed Quotes

RVMD Revolution Medicines

Watchlist
  • 44.060
  • +0.770+1.78%
Close Dec 20 16:00 ET
  • 43.800
  • -0.260-0.59%
Post 20:01 ET
8.14BMarket Cap-12.04P/E (TTM)

About Revolution Medicines Company

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Company Profile

SymbolRVMD
Company NameRevolution Medicines
Listing DateFeb 13, 2020
Issue Price17.00
Founded2004
CEODr. Mark A. Goldsmith, M.D., PhD
MarketNASDAQ
Employees378
Fiscal Year Ends12-31
Address700 Saginaw Drive
CityRedwood City
ProvinceCalifornia
CountryUnited States of America
Zip Code94063
Phone1-650-481-6801
Websitehttp://www.revmed.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Mark A. Goldsmith, M.D., PhD
  • President, Chief Executive Officer and Chairman of the Board
  • 10.41M
  • Dr. Wei Lin
  • Chief Medical Officer
  • --
  • Margaret A. Horn, J.D.
  • Chief Operating Officer
  • 4.39M
  • Jack Anders
  • Chief Financial Officer and Principal Accounting Officer
  • 3.05M
  • Ryan Asay
  • Senior Vice President, Corporate Affairs
  • --
  • Dr. Jing Yi, PhD
  • Senior Vice President, Head of Program Leadership.
  • --
  • Xiaolin Wang
  • Executive Vice President, Development
  • 3.23M
  • Dr. Mason Shih, M.D.
  • Senior Vice President, Head of Drug Safety
  • --
  • Dr. Mary Pinder-Schenck, M.D.
  • Senior Vice President, Head of Medical Affairs
  • --
  • Jeff Cislini
  • Senior Vice President, General Counsel and Secretary
  • --
  • Dr. Stephen M. Kelsey, F.R.C.P.,M.D.
  • President, Research and Development
  • 4.39M
  • Dr. Barbara L. Weber, M.D.
  • Independent Director
  • 480.19K
  • Frank K. Clyburn, Jr
  • Independent Director
  • --
  • Alexis A. Borisy, A.M.
  • Lead Independent Director
  • 510.63K
  • Elizabeth McKee Anderson, M.B.A.
  • Independent Director
  • 483.78K
  • Dr. Sandra J. Horning, M.D.
  • Independent Director
  • 720.00K
  • Dr. Flavia Borellini, PhD
  • Independent Director
  • 489.09K
  • Dr. Thilo Schroeder, PhD
  • Independent Director
  • --
  • Dr. Sushil Patel, PhD
  • Independent Director
  • 475.19K
  • Dr. Lorence H. Kim, M.D.
  • Independent Director
  • 489.99K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
MicroStrategy
MSTR
+11.56%
Adobe
ADBE
+2.24%
Salesforce
CRM
+2.21%
Apple
AAPL
+1.88%
Meritage Homes
MTH
+1.78%

Unlock the Full List